1457301
USP
Naproxen
United States Pharmacopeia (USP) Reference Standard
동의어(들):
(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid
로그인조직 및 계약 가격 보기
모든 사진(1)
크기 선택
보기 변경
200 MG
₩610,523
About This Item
Linear Formula:
CH3OC10H6CH(CH3)CO2H
CAS Number:
Molecular Weight:
230.26
Beilstein:
3591068
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
naproxen
제조업체/상표
USP
기술
HPLC: suitable
gas chromatography (GC): suitable
mp
152-154 °C (lit.)
응용 분야
pharmaceutical (small molecule)
형식
neat
SMILES string
COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O
InChI
1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
InChI key
CMWTZPSULFXXJA-VIFPVBQESA-N
유전자 정보
human ... PTGS1(5742) , PTGS2(5743)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Naproxen USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Dexamethasone Compounded Oral Suspension
- Naproxen
- Naproxen Compounded Oral Suspension
- Naproxen Delayed-Release Tablets
- Naproxen Oral Suspension
- Naproxen Tablets
- Terazosin Tablets
생화학적/생리학적 작용
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor.
분석 메모
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
기타 정보
Sales restrictions may apply.
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3
표적 기관
Respiratory system
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
가장 최신 버전 중 하나를 선택하세요:
이미 열람한 고객
Christopher Derry et al.
The Cochrane database of systematic reviews, (1)(1), CD004234-CD004234 (2009-01-23)
Naproxen, a non-steroidal anti-inflammatory drug, is used to treat various painful conditions including postoperative pain, and is often administered as the sodium salt to improve its solubility. This review updates a 2004 Cochrane review showing that naproxen sodium 550 mg
Chuthamanee C Suthisisang et al.
Headache, 50(5), 808-818 (2010-03-20)
To assess the efficacy and safety of naproxen sodium in the treatment of acute migraine attacks. Non-steroidal anti-inflammatory drugs including naproxen sodium have been used in treating migraine attack. A number of clinical trials of naproxen sodium in migraine have
Larisa Kovacevic et al.
Pediatric nephrology (Berlin, Germany), 18(8), 826-829 (2003-05-30)
A 17-year-old healthy girl was admitted to our hospital with diffuse abdominal pain and decreased oral intake of about 11 days duration. About a week prior to admission, she had taken naproxen, 250 mg four times a day for 4
Marta L Capone et al.
Journal of the American College of Cardiology, 45(8), 1295-1301 (2005-04-20)
We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease. The incubation of washed platelets with naproxen for 5
Anke Prudic et al.
Molecular pharmaceutics, 11(11), 4189-4198 (2014-10-09)
The incorporation of poorly soluble active pharmaceutical ingredients (APIs) into excipients (e.g., polymers) to formulate an amorphous solid dispersion is a promising strategy to improve the oral bioavailability of the API. The application of copolymer excipients allows access to combinations
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
